Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer

Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer

Abstract Background Treatment with epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) leads to initial response in most patients with EGFR‐mutated non‐small cell lung cancer (NSCLC). In contrast, little is known of the subpopulation of patients with NSCLC with EGFR mutations w...

Full description

Bibliographic Details
Main Authors: Tadaaki Yamada, Soichi Hirai, Yuki Katayama, Akihiro Yoshimura, Shinsuke Shiotsu, Satoshi Watanabe, Toshiaki Kikuchi, Kazuki Hirose, Yutaka Kubota, Yusuke Chihara, Taishi Harada, Keiko Tanimura, Takayuki Takeda, Nobuyo Tamiya, Yoshiko Kaneko, Junji Uchino, Koichi Takayama
Format: Article
Language:English
Published: Wiley 2019-04-01
Series:Cancer Medicine
Subjects:
biomarker
EGFR mutation
immunology
non‐small cell lung cancer
Online Access:https://doi.org/10.1002/cam4.2037

Internet

https://doi.org/10.1002/cam4.2037

Similar Items